Drugging the undrugable.

How it works

We invented a novel approach to down regulating oncogenes and so far successfully targeted previously thought to be undruggable genes such as Kras. Our approach could be applicable to many if not all oncogenes. We built the technology so that when it is combined with TransSkip and TransJoin, the result of administration of a single drug is the simultaneous activation of the therapeutic transgene and down regulation of the oncogene, giving cancer and other diseases a "one-two punch."

partner with us
Believe in our vision? 
Contact us to see how we can work together
get more info